• HSBC
Page navigation Browse related articles

Neopharma receives approval from UAE Ministry of Health for H1N1 medicine

  • United Arab Emirates: Saturday, September 26 - 2009 at 17:00
  • PRESS RELEASE

Neopharma, the Abu Dhabi-based pharmaceuticals manufacturer, today announced it has received clearance from the UAE Ministry of Health for its antiviral medication Oseltamivir BR Flu.

The ministry's approval for Neopharma's drug comes at a time when the entire region is gripped by fears over the H1N1 pandemic. The drug is a potential choice to prevent and treat H1N1 flu in the region.

His Excellency Abdulla Humaid Al Mazroei, Vice-Chairman, Neopharma, and Dr. B.R. Shetty, Managing Director and CEO, thanked the UAE Ministry of Health on behalf of the Board of Directors of the company.

Dr. Shetty, said:

"The endorsement for the antiviral drug manufactured by Neopharma, a local company, reflects the strong support of the Ministry of Health for the vision of the UAE leadership to create a self-sustaining community. As a leading manufacturer of life-saving drugs, we believe it is our responsibility to play a vital role in helping the community at this critical juncture.


"We are confident the approval for Oseltamivir will significantly facilitate medical professionals and the wider community to effectively tackle the lethal H1N1 virus in the region," he added.

Neopharma's Oseltamivir BR Flu is the outcome of a joint venture with leading pharmaceuticals major Hetero Drugs Ltd and is the first in a series of major life-saving drugs the company plans to produce over the next few years in the region.

Neopharma at present has independent production blocks for the manufacture of general and betalactam products. The company's plant in Abu Dhabi is designed for large-scale production of tablets, capsules and liquid orals.
(From left) Dr. B.R. Shetty, Managing Director and CEO and His Excellency Abdulla Humaid Al Mazroei, Vice Chairman, Neopharma.
(From left) Dr. B.R. Shetty, Managing Director and CEO and His Excellency Abdulla Humaid Al Mazroei, Vice Chairman, Neopharma.
Enlarge »
Article Options
Log in to request more information from Neopharma

Notes and Media Contacts »

About Neopharma:
Neopharma is a premier pharmaceuticals manufacturing company based in Abu Dhabi. Set up in October 2003, Neopharma manufactures a wide range of products including antibiotics, analgesics, respiratory medicines, antihistamines, as well as medications for cardiovascular conditions and diabetes. A robust R&D centre, hi-tech manufacturing and quality embedded operations make the company a manufacturer of world-class pharmaceutical products.

Neopharma has received the prestigious Mohammed bin Rashid Al Maktoum Award in the manufacturing category and is also the recipient of the current European Good Manufacturing Practice Guidelines Certification from Belgium. The company has received the ISO 9001, ISO 14,001 and OHSAS 18,001 certifications for integrated management system encompassing quality, environment and safety standards. These accolades reflect Neopharma's penchant for quality - a key driver for generic pharmaceutical business.

Steered under the visionary leadership of the Board of Directors and Dr. B.R. Shetty, Neopharma is all set to make a foray into the healthcare of the future - biotechnology and nanotechnology based products


For further information, please call:
Zeba Ahmad

JiWin
Tel: +9714 361 3590
Fax: +9714 388 8001

Or

Hammam Alyazji
JiWin
Tel: +9714 3755877

Disclaimer »

Articles in this section are primarily provided directly by the companies appearing or PR agencies which are solely responsible for the content. The companies concerned may use the above content on their respective web sites provided they link back to http://www.ameinfo.com

Any opinions, advice, statements, offers or other information expressed in this section of the AMEinfo.com Web site are those of the authors and do not necessarily reflect the views of AME Info FZ LLC / Emap Limited. AME Info FZ LLC / Emap Limited is not responsible or liable for the content, accuracy or reliability of any material, advice, opinion or statement in this section of the AMEinfo.com Web site.

For details about submitting your stories, please read the guide - all content published is subject to our terms and conditions